Topics
High-grade gliomas | Treatment | Targeted therapy | Anlotinib
Home > Publications > Topics > High-grade gliomas > Treatment > Targeted therapy > Anlotinib
Zhao S, Zhang M, Zhang Q, Wu J, Dai
H.
Anlotinib
alone or in combination with bevacizumab in the treatment of
recurrent high-grade glioma: a prospective single-arm, open-label
phase II trial.
BMC
Cancer. 2024 Jan
2;24(1):6. doi:
10.1186/s12885-023-11776-4. PMID:
38166698. Interventional study. ˍ
Wang Q, Wei W, Ji X, Li J, Wu N, Li J, Sun K, Ma C, Pan H.
Safety
and Efficiency of Anlotinib in Patients with Recurrent Grade 4
Glioma: A Single-Center Retrospective Analysis.
Neurol
India. 2024 Jun 30;72(3):578-584. doi:
10.4103/ni.ni_435_22. PMID:
39041976. Observational study. ˍ